What We're Reading: Page 94
Industry reads hand-picked by our editors
Mar 20, 2023
-
Financial Times
Big Pharma lobbies for slice of US chip industry tax breaks
-
NPR
California enters a contract to make its own affordable insulin
-
Reuters
Novo Nordisk’s diabetes drug Ozempic back in supply in US after months of shortage
-
BioSpace
Novartis, Biogen Scrap Gene Regulation Partnerships with Sangamo
Mar 17, 2023
Mar 16, 2023
-
The Wall Street Journal
Shortage of Last-Ditch Drug for Advanced Prostate Cancer Worries Doctors
-
Reuters
Alzheimer’s Association lobbies for Medicare coverage of Leqembi and other drugs
-
Fierce Biotech
The delisting dilemma: Why do so many biotechs face being kicked off the Nasdaq?
-
WBUR
This Mass. doctor questioned a popular pregnancy drug. Now, he’s been proven right
Mar 15, 2023
-
GeekWire
How Pfizer’s $43 billion acquisition of Seagen could impact the biotech industry in Seattle
-
Evaluate Vantage
Europe rues SVB loss as a cornerstone life science supporter
-
Reuters
How GSK plans to replenish its depleted medicine cabinet
-
Fierce Pharma
Chasing Pfizer, GSK’s 5-in-1 meningococcal vaccine delivers phase 3 trial win
Mar 14, 2023
-
C&EN
Why lecanemab’s success spells the revival of small-molecule Alzheimer’s disease treatments
-
Legal Dive
SVB had no risk chief through much of 2022, proxy statement shows
-
Reuters
U.S. FDA places Mersana’s cancer drug trial on hold following death
-
Bloomberg
Novartis Is Said to Start Sale of Some Ophthalmology Assets
Mar 13, 2023
-
Reuters
Bristol Myers, Pfizer, AbbVie drugs likely to face U.S. price negotiation
-
Stat News
Biogen executive Samantha Budd Haeberlein leaves company
-
Associated Press
Prostate cancer treatment can wait for most men, study finds
-
Spectrum
Biotech downturn hurts companies targeting autism-linked conditions
Mar 10, 2023
-
The Information
Silicon Valley Bank CEO Tells VC Clients to ‘Stay Calm’
-
The Financial Times
Cost of gene treatments for once incurable diseases too high, scientists warn
-
Fortune
Read the letter Lux Capital sent to its investors, warning of ‘crushing consolidation in the venture industry’
-
MIT Technology Review
More than 200 people have been treated with experimental CRISPR therapies
Previous
